Vesalius Biocapital Partners
VC Fund
Strassen, Luxembourg
Vesalius Biocapital Partners is a VC fund in Strassen focused on Biotechnology and Health Care. Vesalius Biocapital Partners invests in companies active in human health through venture capital funds raised since 2007. They have contributed to developing 20 companies since inception.With more than € 150 million under management in two funds. Vesalius Biocapital Partners plays the role of lead investor in the large majority of its financingrounds.Their companies are based in Europe allowing easy interaction with management.They invest in all stages of development and do not shy away from relatively early-stage projects with a sound proprietary technology and corresponding IP, unique team skills and a clear competitive edge based on solid data.
- Total investments:
- 61
- Last investment:
- Lead investor:
- 43%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Vesalius Biocapital Partners invests in
Stages Vesalius Biocapital Partners invests in
Countries Vesalius Biocapital Partners invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $3.9M–$20M
- Series B
- $4.4M–$25M
- Series C
- $7M–$100M
Investment Focus
Industry
- Biotechnology 24 (39%)
- Health Care 22 (36%)
- Medical 11 (18%)
- Therapeutics 8 (13%)
- Pharmaceutical 7 (11%)
Stage
- Series A 16 (26%)
- Series B 15 (25%)
- Series C 10 (16%)
- Funding Round 3 (5%)
- Seed 2 (3%)
Country
- Belgium 8 (13%)
- Germany 7 (11%)
- France 4 (7%)
- United States 4 (7%)
- The Netherlands 4 (7%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Fei Tian
Analyst
|
Analyst | Total investments: 1 | Find email | |
Guy Geldhof
Partner
|
Partner | Total investments: 5 | Find email | |
Stephane Verdood
Managing Partner
|
Managing Partner | Total investments: 8 | Find email | |
Alain Parthoens
Managing Partner
|
Managing Partner | Total investments: 7 | Find email | |
Christian Schneider
Managing Partner
|
Managing Partner | Total investments: 6 | Find email | |
| See all 11 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
ENYO Pharma
|
ENYO Pharma is a biopharmaceutical company incorporated in Jan, 2014, by four scientists of the Infectiology Research Center in Lyon, France, and three seeding partners (2 privates and 1 public).The company is based in the Infectiology Center of Lyonbiopôle in Lyon, France and maintains tight collaborations with the seminal Inserm team and theBSL4 laboratory Inserm-Jean Mérieux.ENYO Pharma has licensed several Inserm patents issued from the discoveries of the founding scientists and developed a unique platform for the identification of intracellular therapeutic targets and molecules.The company is developing treatments against the most important viruses and is thriving to become a global leader in anti-virals. Research and Development is currently focused on human infecting viruses, with the first two programs being dedicated to the treatment of severe and seasonal flu and chronic hepatitis B. The company plans to conduct its molecules to Phase II clinical trials. | $7M / Series C / Jun 12, 2025 | |
Inflammatix
|
Inflammatix develops novel molecular diagnostics for acute infections and sepsis that work by 'reading' the immune system. It is a molecular diagnostics company developing rapid tests that read the immune system to resolve major clinical and public health challenges.They are initially focused on developing tests for acute bacterial andviral infections, and sepsis based on patent-pending biomarkers exclusively licensed from Stanford University. | $57M / Series E / Sep 12, 2024 | |
Caresyntax
|
Caresyntax is a digital surgery platform that enables OR teams to predict and improve surgical performance. Its enterprise-grade digital surgery platform delivers insights to improve patient outcomes by using proprietary software and AI to analyze large volumes of video, audio, images, device data, clinical, and operational data in and around theOR.Caresyntax insights help surgeons benchmark and improve their care, hospital administrators use surgical resources more efficiently, medical device companies advance better products, and insurance companies understand risk and devise more tailored policies. The software is used in more than 4,000 operating rooms worldwide, has supported more than 30,000 surgeons, and improved care for more than 2 million patients. | $80M / Series C / Aug 15, 2024 | |
CatalYm
|
Catalym develops antibodies against a placental factor which is overexpressed by various tumour types. | $150M / Series D / Jul 16, 2024 | |
HepaRegeniX
|
HepaRegeniX is developing drugs for treating acute and chronic liver diseases that effectively restore the regenerative capacity of hepatocytes. The therapeutic concept is founded on research by Professor Lars Zender’s group at the University Hospital Tübingen, which identified mitogen-activated protein (MAP) kinase kinase 4 (MKK4) as a keyregulator of liver regeneration. Work by Professor Zender’s team showed that using small RNA molecules to suppress MKK4 gene expression restored the regenerative capacity of hepatocytes, even in severely diseased livers. Founded in 2015, HepaRegeniX is developing small-molecule MKK4 inhibitors to treat liver disorders, potentially including nonalcoholic steatohepatitis. | $16.3M / Series C / Jul 10, 2024 | |
Memo Therapeutics
|
Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis.Its MemoMAB™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’simmune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery.MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations. | $22M / Series C / May 07, 2024 | |
|
Memo Therapeutics
|
Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis.Its MemoMAB™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’simmune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery.MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations. | $22M / Series C / May 07, 2024 | |
inHEART
|
inHEART is a spin-off from IHU Liryc and Inria, two top-tier research centers respectively in cardiac electrophysiology and digital science and technology, that develops software solutions for medical image analysis and cardiac modeling in heart rhythm disorders. inHEART vision is to make the bridge between radiology and cardiology to become aworldwide leader in image-guided diagnosis, therapy planning and navigation software solutions for heart rhythm disorders. | $11M / Series A / May 06, 2024 | |
Cognivia
|
Tools4Patient (T4P) takes an academic approach to the commercialization of technology centered around the optimization and acceleration of therapeutic drug development programs. The first product launched is Placebell©™, which through a variety of data capture sources and analyses characterizes the individual placebo response in subjects andpatients enrolled in clinical trials.Founded in 2013 and based in Gosselies, Belgium, Tools4Patient is a privately- held innovative company engaged in creating analytical tools with both research and clinical applications. The company strives to improve patient quality of life by supporting physicians’ and pharmaceutical/biotechnology companies’ efforts in identifying the right therapeutic for each individual patient.The company is taking full advantage of its founders’ extensive expertise and experience in drug development. Their experience and that of their extensive professional network of advisors, consultants, and collaborators provide T4P’s core scientists and operational groups with the efficiency, practical know-how, and knowledge required to achieve the company’s objectives. Patients, however, are the essential link in the development of future treatments; T4P could not continue to develop new technologies without them. Therefore, care is taken to ensure that patients are involved at every stage of development, listening constantly to their needs and seeing them as critical stakeholders in the clinical research process. | $16.5M / Venture - Series Unknown / Apr 18, 2024 | |
Tonic App
|
Tonic App is a B2C2B digital health company building a professional ecosystem for medical doctors. Tonic App helps medical doctors to diagnose and treat their patients by curating, for them, in a single mobile platform, the best professional resources from peers, publishers, regulatory bodies, recruiters, providers & the industry. | $11.8M / Series A / Mar 26, 2024 | |
| See all 61 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Vesalius Biocapital Partners invest in?
Vesalius Biocapital Partners invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Series B stage. Most of the 61 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Vesalius Biocapital Partners's check size?
Vesalius Biocapital Partners typically joins rounds of $3.9M–$20M at Series A, $4.4M–$25M at Series B and $7M–$100M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Vesalius Biocapital Partners participates in.
How do I contact Vesalius Biocapital Partners?
Public channels for Vesalius Biocapital Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Vesalius Biocapital Partners?
The team at Vesalius Biocapital Partners includes Fei Tian (Analyst), Guy Geldhof (Partner) and Stephane Verdood (Managing Partner), among 11 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
